LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 2 | A17 | 72 | hr | 1476 | 1349 | 3694 | 0.3652 | -0.0576 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 3 | A17 | 72 | hr | 1476 | 1370 | 3694 | 0.3709 | -0.0481 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1476 | 3782 | 3694 | 1.0238 | 1.0397 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1476 | 3928 | 3694 | 1.0633 | 1.1055 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 1476 | 4096 | 3694 | 1.1088 | 1.1813 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 1 | H05 | 72 | hr | 1476 | 3808 | 3694 | 1.0308 | 1.0514 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 2 | H05 | 72 | hr | 1476 | 3798 | 3694 | 1.0281 | 1.0469 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 3 | H05 | 72 | hr | 1476 | 3754 | 3694 | 1.0162 | 1.0270 |
| SK-BR-3 | NU7441 | 0.12 | uM | LJP5 | 1 | C11 | 72 | hr | 1476 | 3664 | 3694 | 0.9919 | 0.9865 |
| SK-BR-3 | NU7441 | 0.12 | uM | LJP5 | 2 | C11 | 72 | hr | 1476 | 4036 | 3694 | 1.0926 | 1.1542 |
| SK-BR-3 | NU7441 | 0.12 | uM | LJP5 | 3 | C11 | 72 | hr | 1476 | 3577 | 3694 | 0.9683 | 0.9472 |
| SK-BR-3 | Dactolisib | 0.12 | uM | LJP5 | 1 | M17 | 72 | hr | 1476 | 1802 | 3694 | 0.4878 | 0.1467 |
| SK-BR-3 | Dactolisib | 0.12 | uM | LJP5 | 2 | M17 | 72 | hr | 1476 | 1687 | 3694 | 0.4567 | 0.0948 |
| SK-BR-3 | Dactolisib | 0.12 | uM | LJP5 | 3 | M17 | 72 | hr | 1476 | 1799 | 3694 | 0.4870 | 0.1454 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 1 | K17 | 72 | hr | 1476 | 2635 | 3694 | 0.7133 | 0.5224 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 2 | K17 | 72 | hr | 1476 | 2894 | 3694 | 0.7834 | 0.6392 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 3 | K17 | 72 | hr | 1476 | 2939 | 3694 | 0.7956 | 0.6595 |
| SK-BR-3 | Palbociclib | 0.12 | uM | LJP6 | 1 | E17 | 72 | hr | 1476 | 2893 | 3694 | 0.7832 | 0.6387 |
| SK-BR-3 | Palbociclib | 0.12 | uM | LJP6 | 2 | E17 | 72 | hr | 1476 | 3132 | 3694 | 0.8479 | 0.7465 |
| SK-BR-3 | Palbociclib | 0.12 | uM | LJP6 | 3 | E17 | 72 | hr | 1476 | 2968 | 3694 | 0.8035 | 0.6726 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP5 | 1 | C05 | 72 | hr | 1476 | 3273 | 3694 | 0.8860 | 0.8101 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP5 | 2 | C05 | 72 | hr | 1476 | 3368 | 3694 | 0.9117 | 0.8530 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP5 | 3 | C05 | 72 | hr | 1476 | 3470 | 3694 | 0.9394 | 0.8990 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP6 | 1 | E05 | 72 | hr | 1476 | 3341 | 3694 | 0.9044 | 0.8408 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP6 | 2 | E05 | 72 | hr | 1476 | 3557 | 3694 | 0.9629 | 0.9382 |